X0609 4 2026-09-03 1 0001974640 Apogee Therapeutics, Inc. APGE 0001802528 Fairmount Funds Management LLC false 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 1 0 0 0 0001769651 Fairmount Healthcare Fund II L.P. false 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 1 0 0 0 0001830177 Kiselak Tomas false 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 1 0 0 0 0001663607 Harwin Peter Evan false 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 1 0 0 0 0 Common Stock 2026-09-03 4 D 0 340855 D 0 I By Fairmount Healthcare Fund II LP Common Stock 2026-09-03 4 D 0 51166 D 0 I By Tomas Kiselak Common Stock 2026-09-03 4 D 0 51166 D 0 I By Peter Harwin Non-Voting Common Stock 2026-09-03 4 D 0 6743321 D Common Stock 6743321 0 I By Fairmount Healthcare Fund II LP Stock Option (Right to Buy) 17.00 2026-09-03 4 D 0 47758 D 2033-07-13 Common Stock 47758 0 I By Tomas Kiselak Stock Option (Right to Buy) 43.85 2026-09-03 4 D 0 10370 D 2034-06-05 Common Stock 10370 0 I By Tomas Kiselak Stock Option (Right to Buy) 41.66 2026-09-03 4 D 0 14461 D 2035-06-17 Common Stock 14461 0 I By Tomas Kiselak Stock Option (Right to Buy) 85.00 2026-09-03 4 D 0 7657 D 2036-06-09 Common Stock 7657 0 I By Tomas Kiselak Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the "Merger Agreement"), in exchange for a cash payment equal to $135.11 per Share without interest (the "Merger Consideration"). Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. The shares of non-voting common stock had no expiration date and were convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may have been changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not have exceeded 19.99%. As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the "Merger"), or became fully vested in connection with the Merger. Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option. Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock. Fairmount and Fairmount Healthcare Fund II LP may each have been deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak served on the board of directors of the Issuer and is also a Managing Member of Fairmount. /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC 2026-09-03 /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II LP 2026-09-03 /s/ Tomas Kiselak 2026-09-03 /s/ Peter Harwin 2026-09-03